SecBot SecBot
8-K ·Filed Jun 15, 2026

NMRA

Neumora Therapeutics, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed5mo ago SEC0001193125-26-270328
8-K material event: Items 1.01, 2.05
Actionable Insight ▼ Bearish

Expect a sharp decline in NMRA shares on this news as the company's most advanced program has failed. The stock may find some support from the extended cash runway and remaining pipeline, but the lack of a late-stage asset makes the company a high-risk binary story. Monitor for potential strategic alternatives (partnerships, licensing, or M&A) as the board evaluates options. Short-term volatility likely elevated.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.9145
T+0 close · Jun 15, 2026 · via day close
Latest settled
+31.22%
T+60 · $1.20
Vs SPY
+30.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $0.9145entry
  2. T+1 · 5mo ago +70.58%α +71.18% · $1.56
  3. T+5 · 5mo ago +67.30%α +68.69% · $1.53
  4. T+20 · 4mo ago +74.96%α +75.71% · $1.60
  5. T+60 · 2mo ago +31.22%α +30.22% · $1.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies of navacaprant for major depressive disorder failed to achieve statistical significance on the primary endpoint, leading to discontinuation of its lead pipeline asset. The company is implementing a 35% workforce reduction to generate ~$10M in annualized savings, incurring ~$2M in restructuring costs, and amended its loan agreement to extend the interest-only period and adjust liquidity covenants. Cash runway is extended into Q3 2027, but the loss of the most advanced program is a severe setback for this clinical-stage biotech.

Key Facts

  • Phase 3 KOASTAL-2 (n=430) and KOASTAL-3 (n=422) both failed primary endpoint (MADRS change from baseline at week 6); p-values 0.813 and 0.480 respectively
  • Navacaprant development discontinued entirely
  • Workforce reduction of approximately 35% implemented on June 12, 2026
  • Expected annualized cost savings of ~$10 million from the reduction in force
  • One-time restructuring costs of ~$2 million to be incurred in Q2 2026
  • Third Amendment to Loan and Security Agreement with K2 HealthVentures extended interest-only period and modified minimum liquidity covenant (effective July 1, 2026)
  • Cash and cash equivalents expected to provide runway into Q3 2027
  • Pipeline now consists of early-stage programs: NMRA-511 (Alzheimer's agitation, Phase 2b planned by end 2026), NMRA-898 (schizophrenia, Phase 1 data H2 2026), NMRA-215 (obesity, clinical studies by year end 2026)

Financial Impact

Loss of lead pipeline asset eliminates near-term revenue potential; restructuring saves ~$10M annually but signals severe pipeline setback; cash runway extended to Q3 2027 provides ~12-15 months of operating buffer

cash runwayoperating expensespipeline value

Risk Factors

  • Further pipeline failures in remaining early-stage programs (NMRA-511, NMRA-898, NMRA-215)
  • Inability to attract partnership or financing given depleted pipeline
  • Potential need for additional dilutive capital if cash runway proves insufficient
  • Liquidity covenant under amended loan agreement may constrain operations if milestones not met

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-270328
Document: d943192dex991.htm0001193125-26-270328
Document: 0001193125-26-270328-index-headers.html0001193125-26-270328
Document: 0001193125-26-270328-index.html0001193125-26-270328
Document: 0001193125-26-270328.txt0001193125-26-270328

Track record

14 reports on NMRA

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
  3. Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
  5. Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
  6. Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
  7. Aug 14, 202613w ago 8-K Neutral 4/10 No price data
  8. Aug 14, 202613w ago Press Release Neutral 4/10 Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
  9. Jul 27, 202616w ago 8-K Bullish 5/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
  10. Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026